Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MAPKAPK2 | P49137 | 12/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29844710 | 1.00 | GRM5 (0.52) | GRM5NPSR1MAPKAPK2KDM4EPKM | |
| SCHEMBL260853 | 0.88 | NPSR1 (0.45) | GRM5NPSR1MAPKAPK2KDM4EPKM | |
| SCHEMBL29410004 | 0.88 | NPSR1 (0.45) | GRM5NPSR1MAPKAPK2KDM4EPKM | |
| SCHEMBL20046668 | 0.85 | NPSR1 (0.56) | GRM5NPSR1KDM4EPKMALDH1A1 | |
| SCHEMBL3581736 | 0.84 | NPSR1 (0.48) | GRM5NPSR1KDM4EPKMALDH1A1 | |
| SCHEMBL361702 | 0.82 | NPSR1 (0.47) | GRM5NPSR1KDM4EPKMALDH1A1 | |
| SCHEMBL5274364 | 0.82 | NPSR1 (0.47) | GRM5NPSR1KDM4EPKMALDH1A1 | |
| SCHEMBL30504253 | 0.81 | GRM5 (0.51) | GRM5MAPKAPK2PIM1PIM3PIM2 | |
| SCHEMBL19718220 | 0.81 | NPSR1 (0.50) | GRM5NPSR1KDM4EPKMALDH1A1 | |
| SCHEMBL23214139 | 0.81 | NPSR1 (0.45) | GRM5NPSR1KDM4EPKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111892601-B | Pyridopyrazolocinnoline compound and preparation method and application thereof | 陕西大美化工科技有限公司 | 2023-09-26 | — | — | CN | claimed |
| CN-111892597-B | Quinoxalinyl pyridopyrazine compound and preparation method and application thereof | 山西天宏达安医药科技有限公司 | 2023-07-25 | — | — | CN | claimed |
| CN-111925370-B | Pyrazinopyrazoles naphthyridine compound and preparation method and application thereof | 湖北科苑生物药业有限公司 | 2023-07-21 | — | — | CN | claimed |
| CN-111925370-A | Pyrazinopyrazolonaphthyridine compound and preparation method and application thereof | 朱继强 | 2020-11-13 | — | — | CN | claimed |
| CN-111892601-A | Pyridopyrazolo cinnoline compound and preparation method and application thereof | 朱继强 | 2020-11-06 | — | — | CN | claimed |
| CN-111892597-A | Quinoxalinyl pyridopyrazine compound and preparation method and application thereof | 朱继强 | 2020-11-06 | — | — | CN | claimed |
| US-20260138991-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4705298-A2 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | Moma Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12559508-B2 | Semi-saturated bicyclic derivatives and related uses | MOMA THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250230171-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. | 2025-07-17 | — | — | US | disclosed |
| US-20250163068-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4373817-B1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2025-05-21 | — | — | EP | disclosed |
| US-20240374606-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2024-11-14 | — | — | US | disclosed |
| EP-0111151-A1 | Substituted nitropyrazine compounds, process for their preparation and pharmaceutical compositions containing them | MERCK & CO. INC. (US) | 1984-06-20 | — | — | EP | disclosed |
| US-4293552-A | Novel 1-(mono-o-substituted benzoyl)-3-(substituted pyrazinyl) ureas | ELI LILLY AND COMPANY (US) | 1981-10-06 | — | — | US | disclosed |
| US-RE30563-E | Preparation of benzoylureas | ELI LILLY AND COMPANY (US) | 1981-03-31 | — | — | US | disclosed |
| US-4160834-A | INSECTICIDES | ELI LILLY AND COMPANY (US) | 1979-07-10 | — | — | US | disclosed |
| US-4133956-A | Preparation of benzoylureas | ELI LILLY AND COMPANY (US) | 1979-01-09 | — | — | US | disclosed |
| US-4083977-A | Novel insecticidal 1-(substituted benzoyl)-3-(substituted pyrazinyl)ureas | ELI LILLY AND COMPANY (US) | 1978-04-11 | — | — | US | disclosed |
| US-3954753-A | SEDATIVES, MUSCLE RELAXANTS, ANTICONVULSANTS | HOFFMANN-LA ROCHE INC. (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230171-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | POLQ, POLB, POLK | GRM5 3951/4885NPSR1 3684/4885MAPKAPK2 3254/4885 |
| US-20260138991-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | POLA1, SUB1, CTDSP1 | GRM5 4487/4885NPSR1 2254/4885MAPKAPK2 4787/4885 |
| US-12559508-B2 | Semi-saturated bicyclic derivatives and related uses | POLA1, CTDSP1, SUB1 | GRM5 4767/4885NPSR1 2680/4885MAPKAPK2 4654/4885 |
| US-20250163068-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | GRM5 179/4885NPSR1 1382/4885MAPKAPK2 3210/4885 |
| US-20240374606-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | PDXK, PGK1, PGK2 | GRM5 1780/4885NPSR1 4432/4885MAPKAPK2 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.